Clinical trials
Newly Diagnosed Multiple Myeloma clinical trials
Below are recruiting newly diagnosed multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 94 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06140966RecruitingPhase 2
Daratumumab and Carfilzomib combo for high-risk multiple myeloma
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
Wuhan, HubeiAges 18–70 - NCT06142396RecruitingEarly Phase 1
Dara-CyBorD for New Multiple Myeloma with Kidney Failure
This pilot study tests a combination of four drugs (daratumumab, cyclophosphamide, bortezomib, and dexamethasone, known as Dara-CyBorD) in people newly diagnosed with multiple myeloma who also have kidney problems. The goal is to see if this treatment is safe and effective for this specific group.
Augusta, GeorgiaAges 18–80 - NCT06149910Recruiting
Study of Treatment Plans for Newly Diagnosed Multiple Myeloma
This study looks at whether a new treatment plan (called a clinical pathway) helps doctors make better decisions for people just diagnosed with multiple myeloma. It will review medical records and may ask you to use a secure online platform to share your health information.
Seattle, WashingtonAges 18 years+ - NCT06158269RecruitingPhase 2
DVRd treatment for newly diagnosed double-hit myeloma
This trial tests a combination of four drugs (daratumumab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with a high-risk form of multiple myeloma called double-hit myeloma. It aims to see if this drug combo can improve outcomes for those with two or more high-risk genetic changes.
TianjinAges 18–70 - NCT06182774RecruitingPhase 3
Fixed vs ongoing treatment for older adults with new myeloma
This trial compares stopping treatment after a set number of cycles versus continuing it for people over 65 or those who cannot have a stem cell transplant. It tests whether a fixed treatment period works as well as long-term treatment for newly diagnosed multiple myeloma.
Edmonton, AlbertaAges 18 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT06216158RecruitingPhase 3
Iberdomide with or without isatuximab after stem cell transplant for multiple myeloma
This trial tests whether adding the drug isatuximab to iberdomide maintenance therapy after a stem cell transplant can help keep multiple myeloma from coming back. It is for people who have already had certain standard treatments and have at least a partial response.
KremsAges 18 years+ - NCT06376526RecruitingPhase 2
Immunotherapy for newly diagnosed multiple myeloma
This trial tests a new combination treatment for people with newly diagnosed multiple myeloma who have already responded well to initial therapy but still have traces of cancer (MRD-positive). The goal is to see if the new approach can eliminate those remaining cancer cells.
Miami, FloridaAges 18 years+ - NCT06407947RecruitingEarly Phase 1
CT071 for high-risk newly diagnosed multiple myeloma
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06409702RecruitingPhase 4
Treating high-risk multiple myeloma with MRD testing
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
Suzhou, JiangsuAges 18 years+ - NCT05623020RecruitingPhase 3
New treatment for newly diagnosed transplant-ineligible myeloma
This Phase 3 study compares a three-drug combination (elranatamab, daratumumab, and lenalidomide) versus a standard three-drug treatment (daratumumab, bortezomib, lenalidomide, plus dexamethasone). It aims to see which plan works better for people newly diagnosed with multiple myeloma who cannot get a stem cell transplant.
Jupiter, FloridaAges 18 years+ - NCT06497738Recruiting
Comparing two drug combos for elderly myeloma
This trial compares two different drug combinations (DRd and VRd-lite) for older adults (65+) who are newly diagnosed with multiple myeloma. The goal is to see which combination works better and is easier to tolerate.
Changzhou, JiangsuAges 65 years+ - NCT06517017RecruitingPhase 2
Gentle combination therapy for frail myeloma patients
This study tests a combination of three drugs (isatuximab, dexamethasone, and lenalidomide) given at a slow, gentle pace for people with multiple myeloma who are considered very frail. The goal is to see if this gentler approach works well and is safe for those who may not tolerate stronger treatments.
Salt Lake City, UtahAges 18 years+ - NCT06679101RecruitingPhase 3
Belantamab combination vs standard care for newly diagnosed multiple myeloma
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
Mobile, AlabamaAges 18 years+ - NCT06698887Recruiting
Long-term safety study of idecabtagene vicleucel for multiple myeloma in Korea
This study follows up on Korean adults with multiple myeloma who received the CAR T-cell therapy idecabtagene vicleucel (also called Ide-cel) in a previous trial (KarMMa-9) and did not have an optimal response after a stem cell transplant. The goal is to monitor long-term safety.
Hwasun, JeonranamdoAges 18 years+ - NCT06758375RecruitingPhase 2
Low dose teclistamab for newly diagnosed multiple myeloma
This trial tests a lower dose of the drug teclistamab in people newly diagnosed with multiple myeloma. It aims to see if a lower dose is still effective and has fewer side effects.
Monterrey, Nuevo LeónAges 18 years+ - NCT06879379RecruitingPhase 2/Phase 3
KPD Consolidation After Stem Cell Transplant for Newly Diagnosed Myeloma
This trial tests a new way to treat multiple myeloma after a stem cell transplant. It uses a combination of drugs (KPD) to help keep the disease from coming back.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06918002RecruitingPhase 3
Comparing elranatamab with standard care for newly diagnosed multiple myeloma
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
AmiensAges 18–69 - NCT06974786RecruitingPhase 2
T-cell engager vs stem cell transplant for newly diagnosed myeloma
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
Birmingham, AlabamaAges 19 years+ - NCT06988020Recruiting
Using MRI to find bone lesions in multiple myeloma
This study tests a new way to make MRI scans look like CT scans to find bone damage from multiple myeloma. You may join if you have just been diagnosed or if your disease came back after strong treatments, and you need bone imaging for staging.
BrusselsAges 18 years+ - NCT06993675RecruitingPhase 2
T-cell therapy for MRD in newly diagnosed myeloma patients after transplant
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
New Haven, ConnecticutAges 18 years+ - NCT06997081RecruitingPhase 2
ERd combination for newly diagnosed multiple myeloma
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
Miami, FloridaAges 18 years+ - NCT07095452RecruitingPhase 2/Phase 3
Newly diagnosed myeloma: comparing drug combinations for non-transplant patients
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Scottsdale, ArizonaAges 18 years+ - NCT07099391RecruitingPhase 1/Phase 2
Study of two drug combos for newly diagnosed multiple myeloma
This trial tests two combinations of drugs (Dara-RVd and Teclistamab-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if adding a newer drug called Teclistamab improves outcomes.
Basking Ridge, New JerseyAges 18 years+
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for newly diagnosed multiple myeloma?
- Yes. Clin2 currently lists 94 recruiting newly diagnosed multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a newly diagnosed multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a newly diagnosed multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.